Cellular and Molecular Therapeutics

The Cellular and Molecular Therapeutics Laboratory, led by Dr. John F. Tisdale, is working on multiple strategies both in the laboratory and in the clinic to cure sickle cell disease by repairing or replacing the precursor bone marrow cells that give rise to sickled red blood cells.
In addition, strategies to correct the underlying mutation which causes sickle cell disease are being pursued utilizing newly developed gene editing tools, and work in the laboratory to develop methods for efficient editing of hematopoietic stem cells is underway.

John Tisdale, M.D.

Senior Investigator and Director

Email

Meet the Team

Contact us

Clinical Trials and Studies

Collection and Storage of Umbilical Cord Stem Cells for Treatment of Sickle Cell Disease

Recruiting

Adult

All Genders

Accepting Healthy Volunteers

Are you pregnant and willing to donate umbilical cord blood to support future sickle cell disease therapies? This study seeks to determine the best way to collect, store, and handle blood from newborns to help researchers improve future sickle cell disease therapies. To participate in this study, you must be pregnant, 45 years old or younger, and willing to donate umbilical cord blood from your newborn. Newborns may be healthy or at risk for sickle cell disease or sickle cell trait. This study is located in Bethesda, Maryland.

Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia

Recruiting

All Ages

All Genders

Accepting Healthy Volunteers

Are you or your child at least 13 years old and have sickle cell disease? Do you or your child have sickle cell disease or beta-thalassemia? Researchers are testing whether a new antibody therapy prior to stem cell transplantation improves the success of the stem cell transplant in individuals at high risk for complications. Participants must be 13 years old or older. The study is taking place at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Patients who have the stem cell transplant must live within 1 hour of the NIH Clinical Center for 3 months after the transplant.
The stem cells for the transplant come from a fully matched donor, 4 years old or older. Donors may provide blood samples for research.

Meet the Team

John Tisdale, M.D.

Senior Investigator and Director

John Tisdale graduated from the College of Charleston in South Carolina with a B.A. in chemistry in 1986. He then earned his M.D. from the Medical University of South Carolina in 1990. He did his internship and residency at Vanderbilt University School of Medicine and was Chief Resident at the Nashville Veterans Administration Medical Center from 1993 to 1994. He joined the NHLBI in 1994, where he has been a hematology fellow, senior staff fellow, and Clinical Investigator. He joined the Molecular and Clinical Hematology Branch of the National Institute of Diabetes and Digestive and Kidney Diseases in 1998 as a tenure track Investigator and was tenured in 2007. In 2011 the College of Charleston recognized Dr. Tisdale with the Alumni of the Year Award and the Pre-Medical Society’s Outstanding Service Award in Medicine. He was recently elected to the American Society for Clinical Investigation and is a member of the American Society of Hematology. Dr. Tisdale has authored or coauthored more than 140 papers.